The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients.
Özet
Background: Glioblastoma multiforme (GBM) is the most common primary
brain tumor characterized with poor prognosis and short survival. In addition
to the standard treatment protocols, targeted molecular treatment options are
under trial. In the recent trials, erythropoietin and erythropoietin receptor were
found to be linked with the progression of GBM cells. Aim: In this study, we
compared the expression of EPOR with survival in GBM patients with mortality.
Materials and Methods: Twenty‑six patients operated for GBM in 2012–2014
were enrolled in this study. Tumor tissues were stained with EPOR, epidermal
growth factor receptor, vascular endothelial growth factor, and assigned
as (1+), (2+), and (3+) according to their immunohistochemical staining levels. The
average postoperative follow‑up time was 9.3 months. Kaplan–Meier’s survival test
and Spearman’s correlation test were used in statistical analysis. Results: EPOR
1(+) stained group showed a median survival of 8 months (95% confidence
interval [CI]: 0.954–15.046). EPOR 2(+) stained group showed a median
survival of 6 months (95% CI: 2.901–9.090) EPOR 3(+) stained group showed a
median survival of 2 months (95% CI: 0.400–3.600). (Kaplan–Meier P = 0.002).
Conclusion: These results portrayed that EPOR staining levels were inversely
proportional with average survival time. In the future, specific inhibitors of this
molecule could be used to form a novel treatment option for GBM.
